Highlights and Quick Summary
- Consolidated Net Income/Loss for the quarter ending September 30, 2022 was $-13.7 Million (a -13.43% decrease compared to previous quarter)
- Year-over-year quarterly Consolidated Net Income/Loss increased by 3.14%
- Annual Consolidated Net Income/Loss for 2021 was $-43.2 Million (a 37.67% increase from previous year)
- Annual Consolidated Net Income/Loss for 2020 was $-31.4 Million (a 2.03% increase from previous year)
- Annual Consolidated Net Income/Loss for 2019 was $-30.7 Million (a 17.43% increase from previous year)
- Twelve month Consolidated Net Income/Loss ending September 30, 2022 was $-58.4 Million (a 3.89% increase compared to previous quarter)
- Twelve month trailing Consolidated Net Income/Loss increased by 35.29% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| $-58.4 Million | $-56.2 Million | $-51.8 Million | $-43.2 Million |
Visit stockrow.com/BDSX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Consolidated Net Income/Loss of Biodesix, Inc.
Most recent Consolidated Net Income/Lossof BDSX including historical data for past 10 years.Interactive Chart of Consolidated Net Income/Loss of Biodesix, Inc.
Biodesix, Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | $-13.7 | $-15.82 | $-15.59 | – |
| 2021 | $-13.28 | $-11.51 | $-11.4 | $-6.96 | $-43.16 |
| 2020 | $-4.53 | $-8.85 | $-8.27 | $-9.71 | $-31.35 |
| 2019 | – | – | $-6.53 | $-9.6 | $-30.73 |
| 2018 | – | – | – | – | $-26.17 |
Business Profile of Biodesix, Inc.
Sector: Healthcare
Industry: Diagnostics & Research